Eli Lilly & Co. Boosts Suzhou Plant with $211M to Meet Diabetes and Obesity Drug Demand
Eli Lilly & Co.(NYSE: LLY)’s China subsidiary is poised to invest a substantial RMB 1.5...
Obesity
Kailera Therapeutics Emerges with USD 400 Million in Series A Funding for Anti-Obesity Pipeline
Kailera Therapeutics, a newly launched US-based biotechnology company, secured USD 400 million in Series A...
Ascletis Pharma Initiates Phase I Trials for Monthly Subcutaneous and Daily Oral Obesity Treatment ASC30 in the US
Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced the dosing...
Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting
Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...
Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments
Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked...
Manufacturing Challenges for Novo Nordisk’s Ozempic Impact Diabetes and Obesity Treatments in Europe
Novo Nordisk (NYSE: NVO), a leading Danish pharmaceutical company, has released a joint statement with...
Novo Nordisk to Resubmit Wegovy Heart Failure Application with Updated Clinical Data
Denmark’s pharmaceutical giant, Novo Nordisk (NYSE: NVO), has reported significant findings on the efficacy of...
Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts
Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...
JiAnTeBo and Sanyou Biopharmaceuticals Join Forces to Discover Metabolic Disease Targets and Develop Agonistic Antibodies
Guangdong JiAnTeBo Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a strategic partnership...
Novo Nordisk’s Wegovy Approved in the UK to Reduce Cardiovascular Risks in Overweight Adults
Novo Nordisk (NYSE: NVO)’s anti-obesity drug Wegovy (semaglutide) has received a new indication approval in...
Eli Lilly’s Mounjaro Approved by China’s NMPA for Long-Term Weight Management
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the US, has announced...
Pfizer’s Once-Daily Danuglipron Selected for Full Clinical Development for Type 2 Diabetes and Obesity
Pfizer Inc. (NSE: PFIZER), a leading pharmaceutical company in the U.S., has announced that a...
Semaglutide Use Linked to Rare Eye Condition NAION in New Study
A recent study has identified a potential link between the use of GLP-1-targeted diabetes and...
Eli Lilly & Co. Strikes Deal for Radionetics’ GPCR-Targeted Radiopharmaceuticals
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the US, has...
Boehringer Ingelheim Initiates Clinical Trial for Novel Anti-Obesity Drug
Boehringer Ingelheim (BI), a German pharmaceutical company, has announced the commencement of clinical development for...
Moon Biotech Secures Exclusive State-Owned Fund Investment in Series C+ Round
Moon (Guangzhou) Biotech Co., Ltd, a leading microbiome platform company based in China, has reportedly...
Supercede Therapeutics Partners with Shanghai Universities for Anti-Tumor Cachexia Drug Developmen
Fudan University and East China Normal University (ECNU) have entered into a global rights cooperation...
Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval
Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...
Novo Nordisk to Pump USD 4.1 Billion into U.S. Manufacturing Expansion
Novo Nordisk (NYSE: NVO), a Danish biopharmaceutical company, has announced plans to invest USD 4.1...
Gan & Lee Pharmaceuticals’ GZR18 Outperforms Market Similars in Weight Reduction Study
Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced the presentation of...